This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Compound Screening Remove Pharma Companies Remove Therapies Related Topics
Small Molecule Drug Development FDA Approval Clinical Development Licensing Trials Treatment Disease Marketing Research More Related Topics >
article thumbnail

Taking a new approach to tackle neurodegenerative diseases

Drug Discovery World

OCTOBER 4, 2022

New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) to Alzheimer’s disease (AD).

Disease 130
Disease Small Molecule Compound Screening Clinical Development 130
article thumbnail

What to expect from drug discovery and development in 2023

Drug Discovery World

JANUARY 26, 2023

The invasion of Ukraine by Russia was devastating, and its effects were felt throughout pharma as supply chains were disrupted and companies had to pause any operations they were pursuing in those countries, limiting access to medicines in both the near and long term. Despite this, innovation still occurred.

Clinical Trials 246
Clinical Trials Drugs Trials Therapies 246
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 42,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024